PharmaShots | Incisive News in 3 Shots

Subscribe Now

Relapsing-Remitting Multiple Sclerosis

Sanofi's Aubagio (teriflunomide) Receives EC's Approval as First Oral MS Therapy for 1L Treatment with Relapsing-Remitting Multiple Sclerosis in Children and Adolescents

Sanofi's Aubagio (teriflunomide) Receives EC's Approval as First Oral MS Therapy for 1L Treatment with Relapsing-Remitting Multipl...

June 21, 2021

Biogen's Tysabri (natalizumab- SC) Receives EC's Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis

Biogen's Tysabri (natalizumab- SC) Receives EC's Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis

April 8, 2021

Biogen's Plegridy (peginterferon beta-1a- IM) Receives EC's Approval for Relapsing-Remitting MS

Biogen's Plegridy (peginterferon beta-1a- IM) Receives EC's Approval for Relapsing-Remitting MS

December 22, 2020

Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relapsing-Remitting Multiple Sclerosis

Polpharma Signs an Exclusive Worldwide Commercialization Agreement with Sandoz for Proposed Biosimilar Natalizumab to Treat Relaps...

September 3, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us